Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Aug 28, 2014 11:40am

167 Views

Post# 22886268

RE:RE:RE:RE:RE:RE:How Is Dart Playing This Bet

Hi GV: Agreed.

Of course, my main point is that the next trial is the key. It's an either-or proposition with little middle ground.

I think the chances of success in that trial are probably very high. I would like to hear from the company on that issue as they are the ones with the real data and knowledge on that matter.

And I think Dart's bet is placed with us. I think he is clearly betting on success in re-Mace. He really doesn't win if re-Mace fails - only if it is the success we hope it is.

It's a good thing that everyone's interests in this happen to be aligned. That's how I see it.

Bullboard Posts

Dynamic Funds Launches new ETF series on the TSX